Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Safety and efficacy of preoperative chemoradiotherapy versus chemotherapy for resectable gastric cancer: A systematic review and meta-analysis.

Allahdad Khan, Alina Sehar, Shree Rath et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16105

e16105 Background: Gastric cancer (GC), being the 5th most prevalent malignancy globally and 3rd leading cause of cancer related mortality, has an overall...

Harnessing transcriptome signatures and CD103+CD8+ immune infiltration for prognosis and treatment outcomes in anal squamous cell carcinoma.

Ilma Soledad Iseas, Mariano Golubicki, Ezequiel Lacunza et al. Jun 01, 2025 pp. 3524-3524 10.1200/jco.2025.43.16_suppl.3524

3524 Background: Anal squamous cell carcinoma (ASCC) is a rare malignancy linked to high-risk HPV, with rising incidence among younger adults. While immun...

Combining SBRT with GM-CSF and peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors: A single arm, single center, phase II trial.

Min Fan, Boyan Wang, Huiting Li et al. Jun 01, 2025 pp. 8110-8110 10.1200/jco.2025.43.16_suppl.8110

8110 Background: After the failure of first-line treatment, patients with stage IV thymic tumors have a poor prognosis and few therapeutic options. Combin...

Gender-specific trends in disability-adjusted life years (DALYs) and mortality rates of pancreatic cancer in adults aged 70 and older: A Global Burden of Disease analysis (1990-2021).

Rabia Iqbal, Maha Zafar, Husnain Ahmad et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16423

e16423 Background: Pancreatic cancer (PC) is one of the most aggressive malignancies, disproportionately affecting older adults. Leveraging data from the...

Tratuzumab deruxtecan: A real-world study in the treatment of metastatic breast cancer in China.

Kunyu Zhang, Xiuzhi Zhu, Xiaohan Ying et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13095

e13095 Background: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) that has demonstrated improved survival in patients with metast...

Overall survival following enzalutamide resistance in metastatic castration-sensitive versus metastatic castration-resistant prostate cancer.

Taro Iguchi, Taisuke Matsue, Minoru Kato et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17043

e17043 Background: Enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI), significantly prolongs overall survival (OS) in metastatic castra...

Efficacy and safety of imetelstat in transfusion-dependent lower-risk myelodysplastic syndromes: A systematic review and meta-analysis.

Malik Samardali, Ibrahim Shanti, James J. Kim Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18579

e18579 Background: Myelodysplastic syndromes (MDS) are a diverse group of clonal hematopoietic stem cell disorders characterized by blood cytopenia, ineff...

Dual inhibition of HER2 and VEGF pathways in breast cancer: A meta-analysis of outcomes.

Abdur Jamil, Zaheer Qureshi, Millicent Amankwah Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13026

e13026 Background: The vascular endothelial growth factor (VEGF) pathway plays a crucial part in tumor angiogenesis by enhancing the creation of new blood...

Antitumoral immunity in colorectal liver metastases: Histopathological growth patterns and tertiary lymphoid structures.

Mohammed Akil Gani, Ahmet Imrali, Andrew James Clear et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15576

e15576 Background: Tertiary lymphoid structures (TLSs) and histopathological growth pattern (HGP) are potential prognostic histological features of cancer...

8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Alison Yan Zhang, Ian D. Davis, Hayley Thomas et al. Jun 01, 2025 pp. 5090-5090 10.1200/jco.2025.43.16_suppl.5090

5090 Background: We previously reported that ENZA improved overall survival (OS) after median follow-up times of 34 and 68...

Exposure to Di-2-ethylhexyl phthalate and hormone receptor-positive breast cancer incidence.

Lijuan Tang, Yimeng Wang, Zhe Zhang et al. Jun 01, 2025 pp. 10559-10559 10.1200/jco.2025.43.16_suppl.10559

10559 Background: Phthalates are ubiquitous environmental endocrine disruptors. As the predominant phthalate, di-2-ethylhexyl phthalate (DEHP) has been co...

SynKIR-CAR T cell advanced research (STAR)-101 phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma.

Janos Laszlo Tanyi, Andrew R. Haas, Mark H. O'Hara et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps5630

TPS5630 Background: Chimeric antigen receptor (CAR) T cells have transformed treatment of hematologic malignancy but have shown limited efficacy in solid...

Neoadjuvant/adjuvant pembrolizumab and surgery + cesium-131 in recurrent HNSCC: A multicenter phase I/IIb trial.

Emma De Ravin, Hani Samarah, Jennifer Maria Johnson et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18044

e18044 Background: Adjuvant external beam re-irradiation after salvage surgical resection for recurrent head and neck squamous cell carcinoma (HNSCC) is a...

Does cytoplasmic AR-V7 circulating tumor cell (CTC) detection add utility in predicting AR pathway inhibitor benefit in men with mCRPC? A retrospective analysis of the PROPHECY study.

Santosh Gupta, Susan Halabi, Siyuan Guo et al. Jun 01, 2025 pp. 5043-5043 10.1200/jco.2025.43.16_suppl.5043

5043 Background: Androgen receptor splice variant-7 (AR-V7) is a constitutively active truncated protein that emerges during hormone therapy resistance in...

Bridging the gap: Usage patterns and training needs of generative artificial intelligence among oncologists in Argentina.

Federico Losco, Andrea Marchioni, Enrique A. Diaz-Canton et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13714

e13714 Background: Generative Artificial Intelligence (GenAI) is being rapidly integrated into clinical oncology practice. Recent publications highlight i...

Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM).

Rachel Galot, Christophe Le Tourneau, Lisa F. Licitra et al. Jun 01, 2025 pp. 6028-6028 10.1200/jco.2025.43.16_suppl.6028

6028 Background: Platinum-refractory recurrent/metastatic squamous cell carcinoma (R/M SCCHN) has a poor prognosis. Several molecular pathways are dysregu...

Response adapted oncologic surgery following neoadjuvant immunotherapy and chemotherapy for resectable locally advanced oral cavity and oropharyngeal squamous cell carcinoma.

Moneb S. Bughrara, Francis P. Worden, Zachary Buxo et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18107

e18107 Background: Head and neck squamous cell carcinoma (SCC) is the seventh leading cause of cancer worldwide. For patie...

Impact of obesity on immune-related adverse events in patients with diagnosis of triple-negative breast cancer.

Safa Saadat Afridi, Jayalekshmi Jayakumar, Chalothorn Wannaphut et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13156

e13156 Background: Obesity is a significant risk factor for breast cancer and is associated with a poor prognosis. Immune checkpoint inhibitors (ICIs) are...

TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.

Si Shi, Xianjun Yu, Xiaobing Chen et al. Jun 01, 2025 pp. 4159-4159 10.1200/jco.2025.43.16_suppl.4159

4159 Background: Chemotherapy currently serves as the cornerstone for treating metastaticPancreatic Ductal Adenocarcinoma Cancer (mPDAC). Nevertheless, th...

Enhancement of 30-day acute care event prediction model following outpatient chemotherapy using vital signs, lab results, and advanced machine learning: A comparative analysis.

Yusen He, Thomas T Maroney, Chaitanya Gudimalla et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13586

e13586 Background: This study aimed to improve the predictive performance of acute care events within 30 days (ACE30) following outpatient chemotherapy ad...

Impact of immune checkpoint inhibitors (ICI) in biliary tract cancer (BTC): Real-world outcomes and predictive factors.

Amir Sara, Anne M. Noonan, Arjun Mittra et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14653

e14653 Background: ICI with gemcitabine and cisplatin (GC-ICI) has become a first-line (FL) standard of care in BTC following the success of the TOPAZ and...

Active cancer in the era of COVID-19: A multivariable meta-analysis vs non-cancer controls with variant imputation.

David M Favara, James Seymour Morris, Syed FH Shah et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23092

e23092 Background: Patients with active cancer are at increased risk from SARS-CoV-2 infection, yet the influence of recent cancer treatment, tumour subty...

Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma and liposaroma (NCT03886311).

Anmol Dia Agarwal, Samantha Jeffrey, Jason Ballon et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23560

e23560 Background: Advances in gene therapy/immunotherapy present the opportunity to further improve established treatment combinations for soft tissue sa...

AI-based complete blood count model for colorectal cancer detection.

Daniella Araújo, Bruno Aragao Rocha, Bruna Los et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15693

e15693 Background: Early colorectal cancer (CRC) detection is crucial for effective treatment; however, traditional screening methods face challenges. Col...

Dietary polyphenols and the risk of prostate cancer in the prospective Southern Community Cohort Study.

Grace Xu, Heather Munro, Qi Dai et al. Jun 01, 2025 pp. 10518-10518 10.1200/jco.2025.43.16_suppl.10518

10518 Background: In the US, prostate cancer incidence is highest among underrepresented and underserved populations, including Black and low-income popul...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page